Home Stocks PRME Prime Medicine, Inc. Common Stock (NASDAQ: PRME) Healthcare · Biotechnology
— —
Quote unavailable · Price data is temporarily unavailable.
The Quantellect read. The borrow fee is 0.36%. Five active firms cover the stock as of Nov 19, 2026; four active firms with targets average $8.75 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Mixed valuation signals P/S 210.2× vs peer median 13.9×
Momentum Neutral RSI (14) 47.5 (overbought above 70, oversold below 30)
Short interest 26.0% of float FINRA settlement Oct 30, 2026
PRME price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range —
Volume —
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history PRME · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Quantellect signals — · Quantellect signals not available
How PRME compares with its industry Against 592 other US-listed Biotechnology stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsThree-month return was 17.9%, higher than 92% of 558 peers.Peer median −29.9% · As of Nov 17, 2026 Points of cautionTrailing-year return on equity was -373.3%, with only 10% of 554 peers reporting a lower value.Peer median −67.8% · As of Nov 17, 2026 Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Current ratio was 1.79, with only 21% of 498 peers reporting a lower value.Peer median 5.03 · As of Nov 17, 2026 Valuation Mixed valuation signals
Metric PRME Peer median
Profitability Profitability metrics are lower than most peers.
Metric PRME Peer median
Gross margin — 78.4%
Not ranked: only 247 of 592 peers report it
Operating margin — 0.0%
Not ranked: only 443 of 592 peers report it
Net margin 0.0% 0.0%
Higher than 19% of 583 peers
Return on equity −373.3% −67.8%
Bottom 10% of peers Higher than 10% of 554 peers
Growth Growth metrics are higher than most peers.
Metric PRME Peer median
Quarterly sales growth, year over year 3.5% 0.0%
Higher than 71% of 592 peers
5-year sales growth rate −2.3% 11.6%
Not ranked: only 139 of 592 peers report it
Balance sheet Balance sheet metrics are lower than most peers.
Metric PRME Peer median
Momentum Returns are higher than most peers.
Metric PRME Peer median
How to read this The dot marks where PRME ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
5 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 5 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $7.00
Average $8.75
High $11.00
As of Nov 19, 2026 across 4 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast → Earnings history — · Earnings history not available
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.
Date Type Who Action Amount Source
Aug 1, 2025 Insider buy GV 2021 GP, L.L.C. / GV 2021 GP, L.P. / GV 2021, L.P. / Alphabet Inc. Buy $5.0M Form 4 Aug 1, 2025 Insider buy NELSEN ROBERT Buy $10.0M Form 4 Aug 1, 2025 Insider buy ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. Buy $10.0M Form 4 Aug 1, 2025 Insider buy ARCH Venture Partners X, LLC / ARCH Venture Partners X, L.P. / ARCH Venture Partners X Overage, L.P. / ARCH Venture Fund X, L.P. / ARCH Venture Fund X Overage, L.P. / CRANDELL KEITH / Burow Kristina / GILLIS STEVEN Buy $10.0M Form 4 Jun 30, 2025 Insider buy Liu David R. Buy $52.8K Form 4 Jun 23, 2025 Insider buy Liu David R. Buy $45.4K Form 4 Jun 16, 2025 Insider buy Liu David R. Buy $31.2K Form 4 Jun 11, 2025 Insider buy Liu David R. Buy $33.6K Form 4 May 20, 2025 Insider buy Brudnick Richard Buy $23.8K Form 4 May 21, 2025 Insider buy LEE ANN L. Buy $113.0K Form 4 All smart-money activity →
News and press releases Year All 2026 2025 2024 Nov 12, 2026, 4:15 PM ET Nov 12, 2026, 4:01 PM ET Nov 10, 2026, 9:40 PM ET Nov 10, 2026, 4:05 PM ET Nov 9, 2026, 8:00 AM ET Oct 5, 2026, 8:00 AM ET Sep 30, 2026, 10:54 AM ET Sep 24, 2026, 5:30 PM ET Sep 24, 2026, 4:01 PM ET Sep 21, 2026, 7:30 AM ET All PRME news → Company profile Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that
CEO Dr. Allan Reine M.D.
Headquarters Cambridge, MA, United States
Employees 146
IPO date Oct 20, 2022
Sector Healthcare
Industry Biotechnology